Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostate Adenocarcinoma 1

Interventions

Specimen Handling 123Magnetic Resonance Spectroscopy 99Biopsy 72pembrolizumab 58Carboplatin 55Nivolumab 54Cisplatin 53Cyclophosphamide 51Paclitaxel 41Bevacizumab 36Radiotherapy 33Gemcitabine 33Dexamethasone 30Doxorubicin 25atezolizumab 24Fluorouracil 24olaparib 23Rituximab 23Pemetrexed 23fludarabine 22durvalumab 21Radiation 21Cytarabine 21venetoclax 20Vincristine 20Prednisone 20Oxaliplatin 20Ipilimumab 20Injections 20Lenalidomide 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × relugolix × 30 days × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡